my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
14-09-2011: NovAliX announced that it has entered into a multi-year drug research collaboration in the field of trisomy 21 with the Fondation Jérôme Lejeune.
NovAliX will use its expertise and capabilities in medicinal chemistry and structural biology to develop small molecule lead candidates targeting the cystathionine-beta-synthase (CBS). Indeed inhibition of CBS over-expression has been associated with restoration of cognitive impairment in animal models afflicted with trisomy.
"We look forward to progressing our research programs for treating trisomy 21 leveraging NovAliX expertise in structure-based drug design and capabilities in advanced lead generation methodologies" said Dr Henri Bléhaut, Chief Scientific Officer at the Fondation Jérôme Lejeune.
Stephan Jenn, President of NovAliX, said "We are very pleased to investigate a novel research approach for the Down syndrome (trisomy 21) and to support the Fondation Jérôme Lejeune in its efforts to improve patients conditions".
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
NovAliX enters into fragment-based drug discovery alliance with Kyowa Hakko Kirin
NovAliX SAS announced that it has entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan. Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets. Under the terms of the agreement ... more
NovAliX Names Dr Luc Van Hijfte as CSO Drug Discovery
NovAliX has announced that it has appointed pharma research executive Dr Luc Van Hijfte as CSO Drug Discovery.Dr. Van Hijfte brings a wealth of experience in pharmaceutical research with over 25 years spent in drug discovery. He joined from Janssen, a J&J company, where he served as Head o ... more
NovAliX Enters into Multi-Target Integrated Drug Discovery Collaboration with Teijin Pharma
NovAliX SAS announced that it has entered into a multi-target integrated drug discovery collaboration with Teijin Pharma Limited of Tokyo, Japan.Within the alliance the companies will collaborate to develop novel drug candidates against multiple targets across different therapeutic areas. N ... more
Strasbourg, France based NovAliX Group is focusing on the development of enabling chemistry and biophysical technologies to support the pharmaceutical industry’s outsourcing needs from discovery to manufacturing. With X-ray protein crystallography, supramolecular mass spectrometry and organ ... more
NovAliX to Collaborate with the Fondation Jérôme Lejeune on Down Syndrome (Trisomy 21)
NovAliX announced that it has entered into a multi-year drug research collaboration in the field of trisomy 21 with the Fondation Jérôme Lejeune.NovAliX will use its expertise and capabilities in medicinal chemistry and structural biology to develop small molecule lead candidates targeting ... more
Created in 1996 and recognised as being in the Public Interest, the Fondation Jérôme Lejeune works on the research of genetic intellectual disabilities: Trisomy 21 (Down Syndrome), "Cri du chat" syndrome, Fragile X Syndrome, monosomies... In order to find a treatment in the future to cure p ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
